Re:Cognition Health leads the way in fight against Alzheimer’s

In the relentless fight against Alzheimer’s disease, Re:Cognition Health, the HSMA cognitive healthcare provider, has been spearheading several groundbreaking clinical trials that aim to reshape the landscape of early-stage diagnosis and treatment. In the search for new treatments capable of slowing, or ideally stopping, the progression of the disease, Eisai’s CLARITY study for Lecanemab and Eli Lilly’s TRAILBLAZER-ALZ 2 study for Donanemab are two recent examples that have showcased some highly significant outcomes:

Lecanemab

Re:Cognition Health patients contributed to a global study cohort of 1,795 volunteers that proved Lecanemab’s prowess, with participants demonstrating a 27% reduction in progressive cognitive decline over 18 months compared to those on a placebo. Dr Emer MacSweeney, CEO and medical director at Re:Cognition Health, hails Lecanemab – which has now secured FDA approval in the USA – not just as an effective treatment but as the potential gateway to a multitude of further innovative therapies.

Dr Emer MacSweeney of Re:Cognition Health

Donanemab

Re:Cognition Health has led the way in managing UK clinical trial volunteers in the TRAILBLAZER-ALZ 2 trial, which showcased Donanemab’s game-changing impact, demonstrating a 35% reduction in cognitive decline. Up to 60% reduction in rate of decline was seen in those with the mildest disease. TRAILBLAZER-ALZ 6, an ongoing trial at seven Re:Cognition Health centres in the UK and USA, is designed to reduce the risk of ARIA (amyloid-related imaging abnormalities), a side effect of this class of medication.

Dr MacSweeney stresses the critical importance of clinical trials, emphasising the transformative potential of these new-generation medications. Participants have a chance to gain early access to highly promising treatments that, if successful, won’t be available to the public for several years. They also receive regular health monitoring. Whether or not they are ultimately successful, all clinical trials contribute to scientific advancements – the more studies are conducted, the more we learn about the disease and how to prevent it.

Dr MacSweeney says: “Amid the challenging landscape of Alzheimer’s, there’s room for cautious optimism. New-generation medications pioneered through international clinical trials available in the UK, hold the transformative potential to reshape the future for those facing a diagnosis. With the promise of cutting-edge treatments on the horizon, there is hope for a future without Alzheimer’s.”